Live Accenture Plc Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow Verve Therapeutics, Inc.

Get SEC filing alerts via email and in your feed for Verve Therapeutics, Inc.

VERV

Verve Therapeutics, Inc.

About Verve Therapeutics, Inc.

Verve Therapeutics is a clinical-stage biotech developing single-course gene editing medicines targeting liver genes to treat cardiovascular disease. Its pipeline includes therapies for lowering LDL cholesterol and Lp(a), aiming to provide durable, one-time treatments for conditions like familial hypercholesterolemia and ASCVD. Utilizing innovative gene editing, lipid nanoparticle delivery, and human genetic insights, the company seeks to transform cardiovascular care with scalable, permanent solutions.
This description was generated via AI from an annual report. Updated 9 months ago.

Latest SEC Filings from Verve Therapeutics, Inc.

1
1
Verve Therapeutics, Inc. Verve Therapeutics Reports $32.98M Collaboration Revenue and $31.03M Net Loss for Q1 2025

Via official filing (AI summary) | about 1 year ago | 0 comments

2
1
Verve Therapeutics, Inc. Verve Therapeutics Reports Q3 2024 Financial Results, Collaboration Revenue Growth, and Net Loss

Via official filing (AI summary) | over 1 year ago | 0 comments